Nurse Practitioner in Merchantville, NJ Accepting Medicare

4 Nurse Practitioner nurses found. Showing 1 - 4

Dr. Marian W Mote, CPNP Nurse Practitioner - Pediatrics Medicare: Medicare Enrolled Practice Location: Merchantville Pediatrics- A Division Of Cha, 1 S. Centre Street, Suite 100, Merchantville, NJ 08109 Phone: 856-665-7337    Fax: 856-665-3938

Kathryn E Valenzano, NP Nurse Practitioner - Gerontology Medicare: Medicare Enrolled Practice Location: 124 Lexington Ave, Merchantville, NJ 08109 Phone: 856-663-1121    Fax: 856-661-9818

Carol Zehler Pulley, Nurse Practitioner - Gerontology Medicare: Accepting Medicare Assignments Practice Location: 124 Lexington Ave, Merchantville, NJ 08109 Phone: 856-663-1121

Meghan Calavano, Nurse Practitioner - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1 S Centre St, Merchantville, NJ 08109 Phone: 800-978-0808

News Archive

Study finds 30% decline in heart failure hospitalization rate

Being hospitalized for heart failure (HF) was about 30 percent less likely in 2008 than in 1998, according to a study by Yale physicians in the Oct. 19 issue of JAMA. The team also found that the rate of hospitalization for black men dropped at a lower rate, and that one-year mortality rates declined slightly during this period, but remained high.

Sherwin-Williams Chemical Coatings forms partnership with Microban International

Sherwin-Williams Chemical Coatings Division is raising the bar for quality coatings by partnering with Microban International, the global leader in built-in antimicrobial protection, to offer select liquid and powder product finishes with Microban(R) antimicrobial protection. Microban(R) protection works continuously to inhibit the growth of bacteria that can cause stain, odor, discoloration and deterioration of the painted surface.

Aeolus Pharmaceuticals raises $1.65 million from existing institutional shareholders

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the "Units"), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.

Resettlement programs in Oakland not yet successful

Refugees who have fled Burma to live in Oakland, Calif., are at risk of becoming a permanent, poverty-stricken underclass warns a new report released today by researchers at San Francisco State University and the Burma Refugee Family Network (BRFN). The report found that almost 60 percent of Oakland's refugees from Burma are living in extreme poverty.

FDA approves GlaxoSmithKline's antibacterial Altabax

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved its antibacterial Altabax for the topical treatment of impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection.

Read more Medical News

› Verified 1 days ago